Tokyo, Japan

Norimichi Ochi

This inventor holds 5 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignee: Chugai Seiyaku Kabushiki Kaisha. Active years: 2008-2020.

USPTO Granted Patents = 5 

% Patents Active = 40.0


 

Average Co-Inventor Count = 3.1

ph-index = 4

Forward Citations = 110(Granted Patents)


Company Filing History:


Years Active: 2008-2020

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Norimichi Ochi: Innovator in Protein Purification

Introduction

Norimichi Ochi is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of protein purification, holding a total of 5 patents. His work focuses on methods that enhance the efficiency and safety of antibody formulations.

Latest Patents

Ochi's latest patents include a method for removing viruses in a physiologically-active protein-containing sample. This innovative approach involves manufacturing an antibody formulation by binding the antibody to a protein-A or protein-G affinity column. The antibody is then eluted with an acidic eluting solution, preferably of low conductivity. Another notable patent is a protein purification method that follows a similar process, ensuring the removal of DNA contaminants.

Career Highlights

Norimichi Ochi is associated with Chugai Seiyaku Kabushiki Kaisha, a leading company in the pharmaceutical industry. His expertise in protein purification has positioned him as a key figure in the development of advanced therapeutic solutions.

Collaborations

Ochi has collaborated with notable coworkers, including Kozo Takeda and Kimie Ishii. Their combined efforts have contributed to the advancement of innovative techniques in the field.

Conclusion

Norimichi Ochi's work in protein purification and antibody formulation exemplifies the impact of innovation in biotechnology. His patents reflect a commitment to improving health solutions through scientific advancements.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…